Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCureFRA:2US0 27 FCF Yield % is -226.63 as of Jul. 29, 2026. GuruFocus rates FRA:2US0 with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,407 Biotechnology companies, NextCure ranks worse than 95.31% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
NextCure FCF Yield % Related Terms
NextCure FCF Yield % Historical Data
* Premium members only.
The historical data trend for NextCure's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2US0 vs LPCN, VYNE, QNCX: FCF Yield % Comparison
For the Biotechnology subindustry, NextCure's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's FCF Yield % distribution charts can be found below:
* The bar in red indicates where NextCure's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCure (FRA:2US0) has a FCF Yield % of -226.63 as of Jul. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on NextCure and its competitors. According to the industry distribution chart, NextCure ranks #1341 out of 1407 companies in the Biotechnology industry, placing it in the top 95.3%.
Is NextCure's FCF Yield % too high?
NextCure's current FCF Yield % is -226.63. Based on the distribution chart, NextCure ranks #1341 out of 1407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NextCure has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does NextCure's FCF Yield % compare to LPCN and VYNE?
According to the Biotechnology industry distribution chart, NextCure ranks #1341 out of 1407 companies for FCF Yield %. This places NextCure in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on NextCure and its competitors. NextCure's current FCF Yield % is -226.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCure stock overvalued right now?
NextCure (FRA:2US0) has a current FCF Yield % of -226.63. The current FCF Yield % is -226.63. NextCure's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For NextCure (FRA:2US0), the current FCF Yield % is -226.63 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
27GF Score
Get the complete analysis for FRA:2US0
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2US0 has been successfully added to your 
